Enanta Pharmaceuticals, Inc. (ENTA)
ENTA Stock Price Chart
Explore Enanta Pharmaceuticals, Inc. interactive price chart. Choose custom timeframes to analyze ENTA price movements and trends.
ENTA Company Profile
Discover essential business fundamentals and corporate details for Enanta Pharmaceuticals, Inc. (ENTA) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
21 Mar 2013
Employees
131.00
Website
https://www.enanta.comCEO
Jay R. Luly
Description
Enanta Pharmaceuticals, Inc. is a biotechnology firm dedicated to discovering and advancing small molecule therapies designed to combat a range of viral infections and various liver conditions. Its research and development efforts are primarily focused on addressing pathogens such as respiratory syncytial virus (RSV), SARS-CoV-2, human metapneumovirus (hMPV), and the hepatitis B virus (HBV). The company also holds a strategic partnership and licensing agreement with Abbott Laboratories. This collaboration involves the joint identification, development, and market introduction of specific HCV NS3 and NS3/4A protease inhibitor compounds, including known agents like paritaprevir and glecaprevir, which are utilized in the management of chronic hepatitis C virus. Founded in 1995, Enanta Pharmaceuticals, Inc. operates from its principal office located in Watertown, Massachusetts.
ENTA Financial Timeline
Browse a chronological timeline of Enanta Pharmaceuticals, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 10 Aug 2026
EPS estimate is -$0.51, while revenue estimate is $16.76m.
Earnings released on 11 May 2026
EPS came in at -$0.45 surpassing the estimated -$0.46 by +2.17%, while revenue for the quarter reached $17.16m , beating expectations by +0.77%.
Earnings released on 9 Feb 2026
EPS came in at -$0.42 surpassing the estimated -$0.54 by +22.22%, while revenue for the quarter reached $18.62m , beating expectations by +17.04%.
Earnings released on 17 Nov 2025
EPS came in at -$0.87 surpassing the estimated -$1.13 by +23.01%, while revenue for the quarter reached $15.13m , missing expectations by -5.29%.
Earnings released on 11 Aug 2025
EPS came in at -$0.85 surpassing the estimated -$1.25 by +32.00%, while revenue for the quarter reached $18.31m , beating expectations by +14.67%.
Earnings released on 12 May 2025
EPS came in at -$1.06 falling short of the estimated -$1.04 by -1.92%, while revenue for the quarter reached $14.93m , missing expectations by -6.48%.
Earnings released on 10 Feb 2025
EPS came in at -$1.05 surpassing the estimated -$1.16 by +9.48%, while revenue for the quarter reached $16.96m , missing expectations by -1.68%.
Earnings released on 25 Nov 2024
EPS came in at -$1.36 falling short of the estimated -$1.16 by -17.24%, while revenue for the quarter reached $67.64m , beating expectations by +277.22%.
Earnings released on 5 Aug 2024
EPS came in at -$1.07 surpassing the estimated -$1.49 by +28.19%, while revenue for the quarter reached $17.97m , beating expectations by +0.96%.
Earnings released on 6 May 2024
EPS came in at -$1.47 falling short of the estimated -$1.26 by -16.67%, while revenue for the quarter reached $17.05m , beating expectations by +3.23%.
Earnings released on 7 Feb 2024
EPS came in at -$1.58 falling short of the estimated -$1.18 by -33.90%, while revenue for the quarter reached $18.00m , missing expectations by -17.98%.
Earnings released on 20 Nov 2023
EPS came in at -$1.33 surpassing the estimated -$2.11 by +36.97%, while revenue for the quarter reached $18.93m , missing expectations by -8.10%.
Earnings released on 7 Aug 2023
EPS came in at -$1.86 surpassing the estimated -$2.38 by +21.85%, while revenue for the quarter reached $18.89m , missing expectations by -8.56%.
Earnings released on 8 May 2023
EPS came in at -$1.79 surpassing the estimated -$1.91 by +6.28%, while revenue for the quarter reached $17.80m , missing expectations by -7.22%.
Earnings released on 7 Feb 2023
EPS came in at -$1.39 surpassing the estimated -$1.52 by +8.55%, while revenue for the quarter reached $23.59m , beating expectations by +0.14%.
Earnings released on 21 Nov 2022
EPS came in at -$1.27 surpassing the estimated -$1.37 by +7.30%, while revenue for the quarter reached $20.32m , missing expectations by -12.16%.
Earnings released on 8 Aug 2022
EPS came in at -$1.53 falling short of the estimated -$1.36 by -12.50%, while revenue for the quarter reached $19.48m , missing expectations by -5.68%.
Earnings released on 9 May 2022
EPS came in at -$1.63 falling short of the estimated -$1.43 by -13.99%, while revenue for the quarter reached $18.72m , missing expectations by -9.44%.
Earnings released on 8 Feb 2022
EPS came in at -$1.48 falling short of the estimated -$1.13 by -30.97%, while revenue for the quarter reached $27.65m , beating expectations by +1.03%.
Earnings released on 22 Nov 2021
EPS came in at -$1.22 surpassing the estimated -$1.31 by +6.87%, while revenue for the quarter reached $23.58m , missing expectations by -13.93%.
Earnings released on 5 Aug 2021
EPS came in at -$1.19 surpassing the estimated -$1.41 by +15.60%, while revenue for the quarter reached $21.62m , missing expectations by -1.08%.
ENTA Stock Performance
Access detailed ENTA performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
